The Biotherapies and Bioproduction of Innovative Therapies (BBTI) Research Program (PEPR), launched by the French government in 2021, is one of the major initiatives in the Biotherapies and Bioproduction of Innovative Therapies acceleration strategy of the France 2030 plan.
This research program, whose scientific management has been entrusted to Inserm and CEA, aims to contribute to the development of tomorrow’s biotherapies and associated key technologies.
It also aims to federate the national academic research ecosystem and promotes close links with industry and hospitals.
The PEPR is part of a wider drive to consolidate France’s leadership and competitiveness in this sector research and manufacturing processes.
Latest news
Highlights from the 2025 PEPR Biotherapies Annual Meeting
September 30th and October 1st, 2025 MO.CO. Pancée, Montpellier The PEPR Biotherapies Annual Meeting was held on September 30th and October 1st, 2025, bringing together all members of the PEPR community. The event stood out for the richness of its discussions, the diversity of presentations and the spotlight on new projects supported by the program.…
Announcement of the Laureates from the First Call for Projects of the PEPR Biotherapies
The PEPR Biotherapies program has launched its first call for projects to support innovative initiatives in the field of biotherapies. After the evaluation process, six ambitious projects promising major advancements in research and healthcare have been selected. These projects will benefit from a total funding of 13.2 million euros.
PhD opportunity – Innovation Gene Therapy for Stargardt Disease
Join an exciting PhD project as part of the EDITO project, working on a novel strategy to treat Stargardt disease, a hereditary macular degeneration caused by mutations in the ABCA4 gene.
Projects
BACTER-EV-BOOSTER
Multidisciplinary approach to stimulate the bioproduction and engineering of Gram+ bacteria’s Extracellular Vesicles (EVs) for therapeutic applications to treat inflammation
Bioengineered Skin-France
Bioengineering of next-generation skin substitutes for cutaneous regeneration
BIOSCALE
Improving the whole chain of large scale AAV bioproduction through disruptive technologies
CARN
Development of biotherapies based on the local delivery of therapeutic RNAs by hybrid functionalized extracellular vesicles (EVs) for musculoskeletal regeneration
iPSC France
Genomic editing of stable universal pluripotent stem cells for allogeneic cell biotherapies
QualAAV
Innovative approaches for quality control to support the industrial deployment of future gene therapy products.
STROMAEV
From engineering of iPS-derived mesenchymal stromal cell-derived extracellular vesicles to clinical translation
